HussainAN. Letter: Cost-per-responder analysis of tralokinumab versus dupilumab for moderate-to-severe atopic dermatitis across Universal Health Care Systems. Dermatitis. 2026:17103568251394011; doi: 10.1177/17103568251394011
2.
SilverbergJI, TothD, BieberT, et al.; ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021; 184(3):450–463; doi: 10.1111/bjd.19573
3.
BlauveltA, de Bruin-WellerM, GooderhamM, et al.Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 52-week, randomised, double-blinded, placebo-controlled, parallel-group trial. Lancet. 2017; 389(10086):2287–2303; doi: 10.1016/S0140-6736(17)31191-1
4.
GuyotP, et al.Number needed to treat and associated costs per additional responder of dupilumab versus tralokinumab in adult patients with moderate-to-severe atopic dermatitis. Value Health. 2024; 27(12 Suppl):S352; doi: 10.1016/j.jval.2024.09.1785
5.
TorresT, Sohrt PetersenA, IvensU, et al.Matching-adjusted indirect comparison of the efficacy at week 32 of tralokinumab and dupilumab in the treatment of moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024; 14(4):983–992; doi: 10.1007/s13555-024-01143-x
6.
TocciG, FerraciniC, BurdenA, et al.Cost per responder of tralokinumab versus dupilumab for atopic dermatitis in Germany, France, Italy, and Spain. Value Health. 2023; 26(12 Suppl):S408; doi: 10.1016/j.jval.2023.09.2139
7.
LaiCPT, Yik WengY. Use of extended dosing intervals of dupilumab in treatment of atopic dermatitis: A systematic review and meta-analysis. Dermatitis. 2025:17103568251367706; doi: 10.1177/17103568251367706
